Bharat Biotech and Ocugen to bring Covaxin in US and Canada
Ocugen intends to continue working with FDA to evaluate regulatory pathways for the pediatric use of Covaxin.
New Delhi: Bharat Biotech a pioneering biotechnology company, on Monday said it, along with its partner Ocugen, is fully committed to bringing COVID-19 vaccine Covaxin in the US and Canada for all age groups. In a statement issued on Twitter, the Hyderabad-based vaccine major said Ocugen's Phase 2/3 Investigational Drug Application for Covaxin has been recently cleared by the US Food and Drug Administration(USFDA) for conducting clinical trials in adults.
Bharat Biotech is a pioneering biotechnology company. The company is known for its R&D and manufacturing capabilities. The company's mission is to deliver affordable, safe and high-quality vaccines and bio-therapeutics that help people prevail over diseases. The company seeks to lead innovation in biotechnology in order to lead the fight against disease with a focus on emerging markets.
Read Also - Bharat Biotech grants Rs 172 crore royalty to ICMR from Covaxin sale
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.